Dipexium Pharmaceuticals Llc (DPRX) 9.72 $DPRX
Global Diabetic Foot Ulcers Therapeutics Pipeline Review 2014
M2 - Mon Apr 28, 4:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/423zx2/diabetic_foot) has announced the addition of the "Global Diabetic Foot Ulcers Therapeutics Pipeline Review 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Foot Ulcers, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Foot Ulcers and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Derma Sciences, Inc. - Cardium Therapeutics, Inc. - GlaxoSmithKline plc - CardioVascular BioTherapeutics, Inc. - Stratatech Corporation - Photopharmica Limited - Tissue Med Biosciences - Reliance Life Sciences Pvt. Ltd. - Nanotherapeutics, Inc. - Celgene Corporation - Kaken Pharmaceutical Co., Ltd. - CytoTools AG - Indus Biotech Private Limited - Phage Pharmaceuticals, Inc. - NovaLead Pharma Pvt. Ltd. - FirstString Research, Inc. - Theravasc, Inc. - CoDa Therapeutics, Inc. - Adocia - EyeGene, Inc. - Izun Pharmaceuticals Corporation - Praxis Pharmaceuticals Inc. - Oneness Biotech Co., Ltd. - Aprogen, Inc. - Pergamum AB - Dipexium Pharmaceuticals LLC - Kasiak Research Pvt. Ltd. Drug Profiles - pexiganan acetate - DermaPro CI-05 - trafermin - WH-1 - DSC-127 - CVBT-141B - doxycycline - GAM-501 - Biochaperone PDGF-BB - CODA-001 - PX-070101 - ReliDerm-DT - PPA-904 - IZN-6D4 - Granexin - CSTC-1 - esmolol hydrochloride - gentamicin sulfate - GSK-1278863 - Fibroblast Growth Factor-1 - PDA-002 - TMBP-3 - coagulation factor XIVa (human) - rusalatide acetate - INDUS-820 - VLD-02 - AP-102 - Drug For Wound Healing - Stromal Cell Therapy For Diabetic Complications - EG-Decorin - Nu-2 - MT-003 - CA5-HIF Gene Therapy for Wound and Ulcers - Cathelicidin - Drug For Diabetic Foot Ulcer - LL-37 - Refaheal For more information visit http://www.researchandmarkets.com/research/42...betic_foot
Dipexium Pharmaceuticals Closes Initial Public Offering
PR Newswire - Tue Mar 18, 10:00AM CDT
Dipexium Pharmaceuticals, Inc. (NASDAQ
PRX), a late stage biopharmaceutical company developing Locilex(TM) (pexiganan acetate cream 1%), a proposed treatment for mild infections of diabetic foot ulcers, today announced the closing of its initial public offering of 3,162,500 shares of its common stock at a public offering price of $12.00 per share.
Dipexium Pharmaceuticals Prices Initial Public Offering of Common Stock
PR Newswire - Thu Mar 13, 7:00AM CDT
Dipexium Pharmaceuticals, Inc. (NASDAQ PRX), a late stage biopharmaceutical company developing Locilex(TM) (pexiganan acetate cream 1%), a proposed treatment for mild infections of diabetic foot ulcers, today announced the pricing of its initial public offering of 2,750,000 shares of its common stock at a public offering price of $12.00 per share. All shares of common stock are being offered by the company. In addition, Dipexium has granted the underwriters a 30-day option to purchase up to an additional 412,500 shares of common stock at the same price to cover over-allotments, if any.
Global Diabetic Foot Ulcers Therapeutics Pipeline Review 2014
M2 - Mon Apr 28, 4:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/423zx2/diabetic_foot) has announced the addition of the "Global Diabetic Foot Ulcers Therapeutics Pipeline Review 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Foot Ulcers, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Foot Ulcers and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Derma Sciences, Inc. - Cardium Therapeutics, Inc. - GlaxoSmithKline plc - CardioVascular BioTherapeutics, Inc. - Stratatech Corporation - Photopharmica Limited - Tissue Med Biosciences - Reliance Life Sciences Pvt. Ltd. - Nanotherapeutics, Inc. - Celgene Corporation - Kaken Pharmaceutical Co., Ltd. - CytoTools AG - Indus Biotech Private Limited - Phage Pharmaceuticals, Inc. - NovaLead Pharma Pvt. Ltd. - FirstString Research, Inc. - Theravasc, Inc. - CoDa Therapeutics, Inc. - Adocia - EyeGene, Inc. - Izun Pharmaceuticals Corporation - Praxis Pharmaceuticals Inc. - Oneness Biotech Co., Ltd. - Aprogen, Inc. - Pergamum AB - Dipexium Pharmaceuticals LLC - Kasiak Research Pvt. Ltd. Drug Profiles - pexiganan acetate - DermaPro CI-05 - trafermin - WH-1 - DSC-127 - CVBT-141B - doxycycline - GAM-501 - Biochaperone PDGF-BB - CODA-001 - PX-070101 - ReliDerm-DT - PPA-904 - IZN-6D4 - Granexin - CSTC-1 - esmolol hydrochloride - gentamicin sulfate - GSK-1278863 - Fibroblast Growth Factor-1 - PDA-002 - TMBP-3 - coagulation factor XIVa (human) - rusalatide acetate - INDUS-820 - VLD-02 - AP-102 - Drug For Wound Healing - Stromal Cell Therapy For Diabetic Complications - EG-Decorin - Nu-2 - MT-003 - CA5-HIF Gene Therapy for Wound and Ulcers - Cathelicidin - Drug For Diabetic Foot Ulcer - LL-37 - Refaheal For more information visit http://www.researchandmarkets.com/research/42...betic_foot
Dipexium Pharmaceuticals Closes Initial Public Offering
PR Newswire - Tue Mar 18, 10:00AM CDT
Dipexium Pharmaceuticals, Inc. (NASDAQ
PRX), a late stage biopharmaceutical company developing Locilex(TM) (pexiganan acetate cream 1%), a proposed treatment for mild infections of diabetic foot ulcers, today announced the closing of its initial public offering of 3,162,500 shares of its common stock at a public offering price of $12.00 per share. Dipexium Pharmaceuticals Prices Initial Public Offering of Common Stock
PR Newswire - Thu Mar 13, 7:00AM CDT
Dipexium Pharmaceuticals, Inc. (NASDAQ
PRX), a late stage biopharmaceutical company developing Locilex(TM) (pexiganan acetate cream 1%), a proposed treatment for mild infections of diabetic foot ulcers, today announced the pricing of its initial public offering of 2,750,000 shares of its common stock at a public offering price of $12.00 per share. All shares of common stock are being offered by the company. In addition, Dipexium has granted the underwriters a 30-day option to purchase up to an additional 412,500 shares of common stock at the same price to cover over-allotments, if any. 
